GeneralConnection.com ➔ Dictionary
Dictionary Search

infliximab

Synonyms

Noun

1. Remicade

2. anti-TNF compound

Usage
Subcutaneous Infliximab for CD by Location - Docwire News
Subcutaneous Infliximab Shows Promise for Durable, Patient-Centered IBD Care - BioPharm International
Subcutaneous Infliximab Recaptures Disease Control After Treatment Interruption in IBD - HCPLive
The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance - AJMC
Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD - Wiley
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial - The Lancet
‘Pleasantly surprised’: Subcutaneous infliximab effective, regardless of Crohn’s location - Healio
Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease – case report - Frontiers
Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients - ASM Journals
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal - PR Newswire
Melkersson-Rosenthal Syndrome: A Case Treated With Infliximab - Cureus
Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111 - Center for Biosimilars
Infliximab, Upadacitinib Offer Rapid Relief in Ulcerative Colitis - Medscape
Early Colectomy After Infliximab in Ulcerative Colitis Linked to C. difficile Infection - Docwire News
Subcutaneous Infliximab May Improve Convenience, Adherence, and Sustained Remission in IBD Care - BioPharm International
Secondary Hemophagocytic Lymphohistiocytosis in a Patient With Crohn’s Disease Receiving Infliximab: A Diagnostic Challenge - Cureus
Accelerated infliximab induction reduces long-term odds of colectomy in ulcerative colitis - Healio
Bilateral Renal Artery Thrombosis in a Patient With Behçet’s Disease Managed With Infliximab Infusions - Cureus
Implications of the First Liquid IV Infliximab Biosimilar - BioPharm International
Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study - Elsevier
Infliximab and Adalimumab Biosimilars Maintain Comparable Safety, Efficacy, Immunogenicity in IBD - Pharmacy Times
Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease - Nature
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW) - PR Newswire
Top 20 Companies in Global Infliximab Biosimilar Market: Strategic Overview and Future Trends (2026–2035) - Spherical Insights
Celltrion launches liquid formulation of Remsima IV in Europe to strengthen infliximab market leadership - koreabiomed.com
A Fulminant Case of Refractory Sarcoidosis Triggered by Infliximab-Neutralizing Antibodies - Cureus
Fulminant Tuberculous Pericarditis Presenting as Cardiac Tamponade in an Infliximab-Treated Patient - Cureus
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab - Business Wire
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday - BioSpace
VIDEO: ‘High index of suspicion,’ liver biopsy help diagnose rare infliximab complication - Healio
Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence - Center for Biosimilars
Successful Treatment of Pediatric Neurosarcoidosis With Corticosteroids, Infliximab, and Methotrexate - ScienceDirect.com
Case Report: Facial Malassezia folliculitis following infliximab treatment in Crohn's disease - Frontiers
Infliximab treatment for autoimmune hepatitis - Clínica FEHV
Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease - NEJM Evidence
Pfizer’s IV Infliximab Biosimilar Approved in NZ - Pearce IP
Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series - Wiley Online Library
FDA Approves First Subcutaneous Infliximab Product - Center for Biosimilars
Infliximab versus Cyclophosphamide for Severe Behçet’s Syndrome - NEJM Evidence
Meta‐Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease - Wiley Online Library
Tracing the historical foundations of infliximab in Crohn’s disease treatment: a cited reference analysis - Frontiers
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration - Nature
Infliximab treatment in pathology-confirmed neurosarcoidosis - Neurology® Journals
Case Studies Highlight Link Between Crohn’s Disease Treatment and IgAN - Docwire News
Celltrion’s Remsima SC First to LATAM Market - Pearce IP
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease - The New England Journal of Medicine
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial - The Lancet
Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis - Nature
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials - The Lancet
Zymfentra, a Subcutaneous Formulation of Infliximab, Approved for IBD - Medical Professionals Reference
Developing ways for doctors to deliver more personalised treatment 2018 - Crohn's & Colitis UK
FDA Approves First Subcutaneous Infliximab for Maintenance Therapy in UC and Crohn Disease - HCPLive
ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease - The Manila Times
Subcutaneous Infliximab Therapy Efficacious for Inflammatory Bowel Disease - Gastroenterology Advisor
Association of the TNFRSF1B -rs1061622 variant with nonresponse to infliximab in ulcerative colitis - Nature
Celltrion’s Remsima cements status as S.Korea’s blockbuster global medicine - KED Global
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome - Nature
Celltrion gains 70% Europe infliximab share as SC formulations surge - CHOSUNBIZ - Chosunbiz
The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab - ASM Journals
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar | Scientific Reports - Nature
Vedolizumab Beats Infliximab as Second-Line Therapy for Ulcerative Colitis - Medscape
Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching - Nature
Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease - Frontiers
Early Crohn's treatment 'could save NHS millions' - BBC
Infliximab Cost - News-Medical
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease - The New England Journal of Medicine
Biosimilars of infliximab - Generics and Biosimilars Initiative
Celltrion's infliximab subcutaneous injection (SC) formulation treatment "Zimpentra" has proven the - 매일경제
Intravenous to Subcutaneous Infliximab Switch Shows Promise in IBD Management - Medscape
Weight Gain on Infliximab Tied to Sex, Crohn Disease, and Disease Severity - Gastroenterology Advisor
Timing of Infliximab Infusion Prior to Surgery and Post-Operative Infections - Rheumatology Advisor
ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S. - PR Newswire
The Remicade Biosimilars Available Now - GoodRx
Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis - Cureus
European Commission Grants Approval of Remsima IV Liquid Formulation, Worlds First Liquid Formulation of IV Infliximab - MEDI:GATE NEWS
Aggressive Infliximab Dosing Shows No Added Benefit in Acute Severe Ulcerative Colitis - Medscape
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union - Biogen
Monocytes from infliximab-resistant patients with Crohn’s disease exhibit a disordered cytokine profile - Nature
Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system - Nature
How Long Does Remicade Take to Work for Ulcerative Colitis? - HealthCentral
Opacity over live vaccines in infants exposed to infliximab - The Lancet
Preventing Crohn's Disease Recurrence Regueiro Report Infliximab - Gastroenterology & Endoscopy News
SC Infliximab Superior to IV Dosage in Patients With Crohn Disease, Ulcerative Colitis - Center for Biosimilars
Case Report: Development of medication-related osteonecrosis of the jaw in a patient on long-term infliximab therapy - Frontiers
Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD - Center for Biosimilars
Treating IBD During Pregnancy - Johns Hopkins Medicine
FDA Approves First Subcutaneous Infliximab for IBD - Managed Healthcare Executive
Anti-NMDAR encephalitis in Crohn’s disease undergoing long-term infliximab treatment: A case report - Frontiers
A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome - Nature
Subcutaneous Infliximab or Vedolizumab maintenance IBD Upadacitinib Crohn's disease Miguel Regueiro - Gastroenterology & Endoscopy News
Infliximab Maintenance Therapy Immunosuppressant - Gastroenterology & Endoscopy News
Moving From IV to Subcutaneous Infliximab, and an Updated Look at Advanced Therapy Safety - Gastroenterology & Endoscopy News
Initial dose of infliximab 5 mg/kg ‘should be adequate’ in most cases of acute severe UC - Healio
VisualAbstract: Dual therapy with infliximab and IVIG in children with multi-system inflammatory syndrome - 2 Minute Medicine
No Difference in Pediatric Growth Rates with Infliximab Biosimilar vs Reference Agent - HCPLive
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis - The New England Journal of Medicine
Celltrion announced on the 19th that its infliximab subcutaneous injection (SC) formulation treatmen.. - 매일경제
Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis - Frontiers
An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease - Science | AAAS
Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar - Neurology® Journals
Foreign Language Equivalents
Foreign Language Equivalents of 'infliximab'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
inflliximab,   infliiximab,   indliximab,   inflixximab,   iinfliximab,   infliixmab,   infkiximab,   inflizimab,   inliximab,   infliximba,   inflxiimab,   inflixmiab,   imfliximab,   inflixiab,   inf;iximab,   influximab,   inflixima,   inflixinab,   onfliximab,   infliximmab,   infliximb,   inflixi,ab,   inffliximab,   infliximsb,   infliximan,   infloximab,   inlfiximab,   inflixomab,   nfliximab,   infliximaab,   infliximabb,   inflicimab,   nifliximab,   inflixumab,   infliximav,   ingliximab,   inflixmab,   infliimab,   unfliximab,   innfliximab,   inflixiimab,   ibfliximab,   inflximab,   infiximab,   inflixiamb,   ifliximab,   infilximab,   ifnliximab
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z